Literature DB >> 26328120

Current medical treatment in pediatric urolithiasis.

Yiğit Akın1, Murat Uçar2, Selçuk Yücel2.   

Abstract

Although the prevalence of urolithiasis is nearly 2-3% in childhood, the risk of recurrence may range from 6.5-54%. There has been an increase in urinary stone disease among pediatric age groups, and stone disease has a multifactorial etiology. After the diagnosis, detailed metabolic evaluation is required. High recurrence rates, therapeutic irregularities and deficiency in diagnosis may lead to comorbidities such as loss of kidney function. Following diagnosis, the requirement for surgery, such as stone extraction and correction of anatomical anomalies, is determined. Medical and supportive treatments are also needed to prevent recurrence and urinary tract infections and to preserve renal function. Supportive care includes increased fluid intake and dietary modifications. Medical treatment is dependent on the cause of the urinary stone disease. The morbidities associated with pediatric urolithiasis can be prevented by early diagnosis, detailed metabolic analysis, regular follow-up and medical treatment protocols.

Entities:  

Keywords:  Children; hypercalciuria; hypocitraturia; oxaluria; urolithiasis

Year:  2013        PMID: 26328120      PMCID: PMC4548612          DOI: 10.5152/tud.2013.063

Source DB:  PubMed          Journal:  Turk J Urol        ISSN: 2149-3235


  50 in total

1.  Bone mineral density and urine calcium excretion among subjects with and without nephrolithiasis.

Authors:  John R Asplin; Kimberly A Bauer; Jennifer Kinder; Georg Müller; Brian J Coe; Joan H Parks; Fredric L Coe
Journal:  Kidney Int       Date:  2003-02       Impact factor: 10.612

2.  Reduction of plasma oxalate levels by oral application of Oxalobacter formigenes in 2 patients with infantile oxalosis.

Authors:  Bernd Hoppe; Katalin Dittlich; Henry Fehrenbach; Georg Plum; Bodo B Beck
Journal:  Am J Kidney Dis       Date:  2011-06-25       Impact factor: 8.860

3.  Urinary stone analysis of 1,000 patients in southern Taiwan.

Authors:  Yii-Her Chou; Ching-Chia Li; Wen-Jeng Wu; Yung-Shun Juan; Shu-Pin Huang; Yung-Chin Lee; Chia-Chu Liu; Wei-Ming Li; Chun-Hsiung Huang; Ai-Wen Chang
Journal:  Kaohsiung J Med Sci       Date:  2007-02       Impact factor: 2.744

4.  Clinical implications of abundant calcium phosphate in routinely analyzed kidney stones.

Authors:  Joan H Parks; Elaine M Worcester; Fredric L Coe; Andrew P Evan; James E Lingeman
Journal:  Kidney Int       Date:  2004-08       Impact factor: 10.612

5.  Bone alterations in children with idiopathic hypercalciuria at the time of diagnosis.

Authors:  Maria-Goretti Moreira Guimarães Penido; Eleonora Moreira Lima; Viviane Santuari Parizotto Marino; Ana-Luiza Fialho Tupinambá; Anderson França; Marcelo Ferraz Oliveira Souto
Journal:  Pediatr Nephrol       Date:  2002-12-19       Impact factor: 3.714

Review 6.  Gout, uric acid and purine metabolism in paediatric nephrology.

Authors:  J S Cameron; F Moro; H A Simmonds
Journal:  Pediatr Nephrol       Date:  1993-02       Impact factor: 3.714

7.  Urolithiasis in pediatric patients.

Authors:  D S Milliner; M E Murphy
Journal:  Mayo Clin Proc       Date:  1993-03       Impact factor: 7.616

Review 8.  Urolithiasis in childhood.

Authors:  M S Polinsky; B A Kaiser; H J Baluarte
Journal:  Pediatr Clin North Am       Date:  1987-06       Impact factor: 3.278

9.  Epidemiology of paediatric renal stone disease in the UK.

Authors:  R J M Coward; C J Peters; P G Duffy; D Corry; M J Kellett; S Choong; W G van't Hoff
Journal:  Arch Dis Child       Date:  2003-11       Impact factor: 3.791

10.  Lowering dietary protein to U.S. Recommended dietary allowance levels reduces urinary calcium excretion and bone resorption in young women.

Authors:  B Avery Ince; Ellen J Anderson; Robert M Neer
Journal:  J Clin Endocrinol Metab       Date:  2004-08       Impact factor: 5.958

View more
  1 in total

1.  Association between dietary pattern and metabolic disorders in children and adolescents with urolithiasis.

Authors:  Mariana S Vieira; Priscila de C Francisco; Ana Luiza L C Hallal; Maria Goretti M G Penido; Nilzete L Bresolin
Journal:  J Pediatr (Rio J)       Date:  2019-02-05       Impact factor: 2.990

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.